Redcare Pharmacy's Profitability Milestone Meets a Market That's Still Not Convinced
Published on 08/03/2026 at 16:25 | Redaktion boerse-global.de
The most telling moment for Redcare Pharmacy this quarter wasn't the headline numbers — it was the market's reaction to them. The online pharmacy posted its strongest adjusted EBITDA margin in a decade, and investors responded by knocking 5.49 percent off the share price on Friday, leaving the stock at 61.95 EUR. That divergence between operational progress and share-price performance has become the defining feature of the company's recent trajectory.
The second-quarter figures themselves were hard to fault. Group revenue climbed 20 percent to 853 million EUR, propelled by a 58 percent surge in the German prescription business, which reached 180 million EUR. Across the entire group, prescription sales hit 339 million EUR, up 34 percent year on year. The adjusted EBITDA margin of 3.5 percent marked a ten-year high, with efficiency gains and tighter cost controls finally outpacing the heavy spending on customer acquisition and logistics that has long weighed on the bottom line. Active customers now number 14.7 million.
A Stock That Has Doubled — And Still Trails Its Peak
The share price tells a more complicated story. At current levels, the stock has more than doubled from its March low of 30.06 EUR, yet it remains nearly 40 percent below the 52-week high of 103.60 EUR reached last August. Over the past twelve months, the shares have lost 37.43 percent, and the recent recovery has lost momentum — the stock shed more than 11 percent over the past 30 days before staging a modest bounce at the start of this week. It currently trades about 2.09 percent above its 50-day moving average of 60.68 EUR.
Analysts see the recent consolidation as a pause rather than a reversal. In early August, nine analysts updated their 2026 forecasts, settling on average revenue of roughly 3.41 billion EUR — an increase of about 6 percent. More striking is the projected swing in earnings: consensus points to a per-share loss of 0.60 EUR, a reduction of up to 70 percent from previous estimates. The improved profitability outlook stems directly from the second-quarter margin performance, which suggests the company's cost discipline is beginning to translate into sustainable earnings power.
The CardLink Effect
Management credits much of the prescription growth to the CardLink system, introduced in May 2024, which lets patients redeem prescriptions directly through the app. Vouchers of up to ten euros per prescription have been deployed to sweeten the switch from traditional pharmacies. CEO Olaf Heinrich has set a medium-term target of an EBITDA margin above 2 percent — a bar the company has already cleared in the most recent quarter.
Some analysts caution that the seasonal growth tailwind may ease slightly in late summer, which could explain the market's guarded response to otherwise strong results. The share price fell 7.40 percent over the seven days following the earnings release, even as the underlying numbers improved.
Just as Redcare is tightening its cost controls to protect margins, many UK employers are discovering gaps in their own compliance documentation that could prove far more expensive. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace risks properly and stay on the right side of health and safety law. Download the free Risk Assessment Toolkit
Regulatory Calendar Looms
The coming weeks could prove decisive for the sector's economics. In August, the Federal Ministry of Health is expected to finalize a legislative package that would raise the fixed fee per prescription. The fee already climbed to 9.00 EUR in July and is slated to rise to 9.50 EUR by early 2027. For Redcare, the reform offers greater planning certainty and could help stabilize margins over the longer term.
The broader pharmacy landscape remains under strain. Traditional brick-and-mortar pharmacies are grappling with rising costs — the minimum wage commission has approved an increase to 14.60 EUR per hour by 2027 — while prescription remuneration has barely moved since 2004, with the last increase of just 25 cents coming in 2013. The Free Pharmacy Association warns that many operations face existential pressure, with chairwoman Daniela Hänel arguing that pharmacies are effectively subsidizing supplier wages. The association has welcomed the new coalition agreement's provisions for a higher fixed surcharge and the removal of the discount ban, though implementation is still pending.
Technical disruptions add another layer of uncertainty. Pharmacy associations in Lower Saxony are demanding more stable e-prescription systems after repeated server failures in the telematics infrastructure caused supply bottlenecks. While access to electronic patient records for pharmacies is being extended from three to seven days, only 56 percent of hospitals have completed the necessary IT updates, according to a survey that has raised concerns about further delays.
Regulatory pressure isn't limited to the pharmacy sector. UK employers face their own compliance minefield — and a single missing risk assessment can trigger substantial fines. Over 37,000 British businesses already use a free toolkit covering fire safety, manual handling, first aid and lone working to keep their documentation in order. Get the free Health & Safety Toolkit
Wide-Ranging Price Targets
The analyst community remains sharply divided on where the stock goes from here. Warburg Research raised its price target to 116.00 EUR following the margin report, while Deutsche Bank sees the shares at 103.00 EUR with a "Buy" rating, citing the improved EBITDA outlook for 2026. UBS takes a far more cautious stance at 74.00 EUR.
The gap between 74 and 116 EUR encapsulates the central debate: how quickly will digital prescription redemption actually scale across Germany? The Health Ministry's decision in August should offer some clarity. For now, Redcare finds itself in an unusual position — delivering its best operational quarter in years while watching its share price drift, as investors wait for the profitability story to become a sustained trend rather than a single quarter's achievement.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
